Recursion Pharmaceuticals Conference Summary Company Overview - **Company**: Recursion Pharmaceuticals (NasdaqGS: RXRX) - **Event**: Jefferies London Healthcare Conference - **Date**: November 18, 2025 Key Points Leadership Transition - Najat Khan has taken over as CEO, with Chris Gibson remaining as Chair of the Board, indicating a smooth leadership transition and continuity in strategic direction [5][8] Strategic Focus Areas 1. **AI-Driven Therapeutics**: The company aims to leverage its integrated AI technology stack to develop differentiated therapeutics, emphasizing the importance of proprietary data generation [6][12] 2. **Operational Discipline**: Recursion has reduced operating costs by 35% while maintaining external catalysts, showcasing a commitment to financial discipline [7] 3. **Talent Acquisition**: The company highlights the importance of having a bilingual team that understands both AI and biology to drive innovation [7][20] Unique Platform and Data Strategy - Recursion differentiates itself by building proprietary datasets, with 65 petabytes of data, 40 petabytes of which are proprietary, allowing for unique AI model development [14][12] - The company has generated over $500 million from partnerships, indicating strong revenue generation for a pre-commercial biotech firm [13] Regulatory Engagement - Recursion is actively engaged with regulatory bodies in the U.S. and EU, particularly in the rare disease and oncology spaces, to navigate evolving guidelines and frameworks [22][23] - The company is focusing on reducing reliance on animal testing through predictive models and organoid approaches [24] Pipeline Highlights 1. **Familial Adenomatous Polyposis (FAP)**: - The company is developing a treatment for FAP, a rare disease affecting approximately 50,000 patients in the U.S. and EU, with promising early data showing a 30-80% reduction in polyps [27][28] - The treatment aims to provide an alternative to colectomy, significantly impacting patient quality of life [27] - Upcoming data expected next month will provide further insights into efficacy and safety [30] 2. **CDK7 and RBM39 Programs**: - The CDK7 program is in monotherapy dose escalation, with early activity observed and a focus on combination therapies in ovarian cancer [41][43] - The RBM39 program is a first-in-class degrader targeting DDR modulation, with early safety and pharmacokinetic data expected in the first half of next year [46] Market Considerations - The company is aware of safety signals related to LVEF depression and rash, common with MEK1/2 inhibitors, and is managing these through established protocols [34] - The potential pivotal program for FAP will likely involve composite endpoints, including polyp burden reduction and progression to surgery [38] Future Outlook - Recursion anticipates a busy 2026 with multiple catalysts and milestones across its pipeline and partnerships, indicating a strong growth trajectory [50] Additional Insights - The company emphasizes the importance of data provenance and model interpretability in regulatory discussions, which is critical for building trust with regulators [20][24] - Recursion's commitment to innovative approaches in drug discovery and development positions it well within the rapidly evolving biotech landscape [19][12]